


IDI BELL



INFORME DEL DIRECTOR

Gabriel Capellá, Director

Desembre, 2019

Agenda

1. Research & Innovation activity summary
2. Research Support
3. Research Organization and changes
4. IDIBELL external evaluations
5. Scientific Advisory Board Meeting – May 2019
6. Follow-up Strategic Plan
7. IRISCAT
8. IDIBELL institutional actions

1

Research & innovation activity summary


- Annual Report 2018
- Evolution of funds
- Highlighted projects 2019
- Internationalization indicators 2019
- Technology transfer projects

Annual Report 2018

Scientific highlights

1260

Scientific articles in indexed journals



6691,60

Total impact factor (JCR 2018)




441

Articles led by IDIBELL researchers

34%
Women leaders

66%
Men leaders



Annual Report 2018

Activity



RESEARCH
PROJECTS

108

National

11

International

GRANTED COMPETITIVE PROJECTS



286 new clinical trials



90 active patents




129 R+D contracts




12 licences

5 active spin-offs

Evolution of funds: Annual budget



Raised funds 2015-2019



Evolution of funds: Annual closing

	2017	2018	Previsio de tancament 2019
a. INCOME	27.319.986,70	27.418.689,04	26.412.305,03
Trustees	4.980.303,60	5.160.303,00	4.560.300,00
Projects	21.993.258,45	21.889.427,15	21.210.532,00
Others	346.424,65	368.958,89	641.473,03
b. EXPENSES	-26.505.260,76	-26.996.207,29	-26.140.666,07
Current expenses	-4.025.660,21	-3.815.074,86	-3.039.250,20
Services	-7.603.829,53	-7.526.781,88	-7.577.260,27
Personnel	-14.875.771,02	-15.654.350,55	-15.524.155,60
c. DEPRECIATION	-465.410,63	-480.978,99	-461.720,16
TOTAL	349.315,31	-58.497,24	-190.081,20
VAT regularization	-679.543,78	-191.798,67	-50.630,80
TOTAL	-330.228,47	-250.295,91	-240.712,00

Project Highlights: National I



AES 2019

- 25 /48 projectes sol·licitats. Import : 2.958.329 €
 - 6/8 contractes Rio Hortega. Import: 322.392 €
 - 3/10 contractes Sara Borrell. Import: 241.794 €
 - 3 intensificacions. Import: 90.000 €
 - 4/9 PFIS concedits. Import: 329.600 €
 - 2/2 projectes investigació clínica. Import: 957.000 €
- Total = 4.899.115€**



MTV3 2019

Total projectes concedits per la MTV3: 43

Total projectes concedits a IDIBELL: 11

6 /25 projectes coordinats: O Casanovas/ O M-Tirado/ C M Pinedo/ R Salazar/ E Duell/ R Zamora

5 projectes com a partners: X M-Guiu-JM Piulats/ L Farré/ C Santos/ C Lázaro/ E Glez-Suárez

Project Highlights: National II



MICIUN 2018

7 projectes concedits (7/9- 78% èxit): I Fabregat/ A Llobet/
X Solé/M Esteller/ O Martínez/S Jimenez/A Rodríguez Fornells
TOTAL: 1.344.310 €

1/5 JOVES INVESTIGADORS DOCTORS

G Capellà (S Crespo)

1/ 6 Contractes per a la intensificació de l'activitat investigadora d'infermeria-L Arribas

2/6 Contractes per a la intensificació de l'activitat investigadora de professionals amb formació sanitària especialitzada (M Gomez-Choco/J Bruna)



PERIS 2018

Project Highlights



- **3 H2020** collaborative projects
IDIBELL budget: **842.951€**
(*F. Fdz. Aranda / X. Bosch / JM Espinás*)



- **1 project** of the Ministry of Education of Saudi Arabia.
IDIBELL Budget: **500.000 €**
(*R. Máñez*)



- **1 “La Caixa Health Research”** project
IDIBELL budget: **416.218 €**
(*M. Graupera*)



- **1 NIH project** as sub-awardee
IDIBELL budget: **289.042 €**
(*G. Capellá*)

Project Highlights: Institutional

FECYT – UCCi activities



Ayudas para el Fomento de la Cultura Científica...

IDIBELL Budget: 25.000 €
40 % co-financed (2019-2020)

PERIS – Go-Europe (internationalization)



”Activitats Científiques d’intenacionalització”

IDIBELL Budget: 261.863 €
(2019-2020)

(PENDING RESOLUTION):

- **FEDER SINGULARS: Implementació de Medicina Personalitzada a IDBELL**
(IDIBELL Budget: **2,124,000 €** - 50% cof.)
- **PECT II: 4LocalHealth** (IDIBELL Budget: **987.073 €** - 50% cof.)
- **UIA: CAPSULH** (95.000€ - 15% cof.)



Ajuntament de L'Hospitalet

Internationalization indicators 2019



12%

Aver. International
People



1,88M€

Aver. € per year



10

Aver. # Projects per
year

(aver. 1 lead
consortium per year;
9% success ratio)



38%

Aver. Intern.
Speakers

(External Seminars)



1







ERC project
hosted at
IDIBELL

Activities to promote internationalization

ACTIVITATS PER INVESTIGADORS ORGANITZADES A 2019

- Sessió “MSCA-IF” – Juliol 2019
- Sessió “H2020 – Work Programme 2020 Health” – Agost 2019
- Sessió “US federal sources for health projects NIH and OTHERS” – Octubre 2019
- Sessió “How to write successful proposals” – Novembre 2019
- Sessió “Defiende tu propuesta.Herramientas del storytelling para la redacción de propuestas de proyectos de ciencia” –Diciembre 2019

NETWORKS WHERE WE HAVE PARTICIPATED

 <p>cost EUROPEAN COOPERATION IN SCIENCE & TECHNOLOGY TN1302: BESTPRAC</p>	 <p>eatris</p>	 <p>CrowdHelix COLLABORATION INTELLIGENCE</p>
 <p>Regic</p>	 <p>ALUMNI MARIE CURIE</p>	 <p>Agència de Gestió d'Ajuts Universitaris i de Recerca AGAUR</p> <p>Grup de Gestors</p>

Active SPIN OFF



Year: 2016 (Dr. Rafa Rosell)

XENOPAT

Year: 2014 (Dr. Villanueva)

START UP



Year: 2008 (Dr. Alemany)



Year: 2017 (Dr. Barrachina)



Year: 2018 (Dr. Máñez)

SPIN OFF projects

Aptadel Tx

(Dr. Martínez-Tirado)

**AngioThera
Gnostics**

(Dr. Casanovas)

Purpose Tx

(Dr. Aran)

Innovation 4 Value



SPEAKERS

PROGRAM

LOCATION


REGISTREI



BARCELONA - November 8th 2019

**The International conference
where healthcare meets innovation**


Total participantes: **278**



Invitados I4V



Perfil de Participantes I4V



Agenda

1. Research & Innovation activity summary
2. **Research Support**
3. Research Organization and changes
4. IDIBELL external evaluations
5. Scientific Advisory Board Meeting – May 2019
6. Follow-up Strategic Plan
7. IRISCAT
8. IDIBELL institutional actions


2



Research support

- Clinical Research
- Core Facilities

IDIBELL Clinical Research



Clinical Research - Activity

	N studies		
UFT·SRC (study coordinator)	46	Anestesia - Clínica Dolor (4) Cardiologia (7) Cirurgia - T. Hepàtic (2) Digestiu (6) Ginecologia (2) Medicina Interna (1)	Nefrologia (1) Neurologia (16) ICO (3) Pneumologia (1) Reumatologia (2) Urologia (1)
Clinical·Research·Window (protocol evaluation)	105	Indústria (80) Independents (25)	
UICEC (monitoring/ pharmacovigilance)	36	Anestesiologia i Reanimació Cardiologia Cirurgia General Digestiu Malalties Infeccioses Nefrologia Neurologia	ICO Pneumologia Psiquiatria Rehabilitació Reumatologia Idibell (Aurora Pujol)
UBiDi (informe estadístic)	82	Anestesia (3) Cardiologia (3) Farmàcia (6) Ginecologia (2) Hematologia (1) Infeccioses(11) Nefrologia (5)	Neurologia (5) ICO (6) Otorinolaringologia (1) Pneumologia (2) Reumatologia (3) Urologia (2) No-IDIBELL (32)

Clinical Research - Activity

		Consultes	Metodològic	Articles	Tesi doctorals	Sessions / Cursos metodologia	Negociació memòria / recursos econòmics
UFT·SRC	109	42	37	17	4	3	6
UBiDi	197	136	40	14		7	

Consultes puntuals	consultes sobre aspectes metodològics / científics de més de 20 minuts de duració que <u>no</u> ha implicat una activitat posterior (redacció de un protocol / realització d'un informe estadístic...)
Metodològic	participació activa en la redacció protocols / beques / SAP (Pla d'anàlisi estadístic) / Programa Desenvolupament Clínic / avaluació resultats
Articles	participació activa en la redacció
Tesi doctorals	director o codirector
Sessions metodologia	sessions de 1 hora aprox. sobre aspectes metodològics als serveis del campus Bellvitge
Cursos metodologia	cursos sobre metodologia (activitat mínim d'una jornada)
Negociació memòria econòmica	"negociació" amb la indústria farmacèutica dels pressupostos proposats al investigador principal per l'assaig clínic
Negociació recursos econòmics	preparació i participació en reunions per la recerca de recursos econòmics amb possibles finançadors d'estudis clínics (indústria / fundacions...)

UIC- ICO

UIC - ICO
Dra Marga García

Activitat Unitat Investigació Clínica		2018			2019 (12/12/19)		
		Dades Eco-Adm	Assaigs en reclutament	pacients	Dades Eco-Adm	Assaigs en reclutament	pacients
Investigadors	Oncologia Mèdica (inclou CSI)		130	334		160	352
Coordinadors	Hematologia		52	96		57	105
Data Entry	Oncologia Radioteràpica		10	45		11	48
	Altres		2	20		1	13
Total			194	495		229	518


Activitat Unitat Funcional Fase 1		2018			2019 (12/12/19)		
		Dades Eco-Adm	Assaigs en reclutament	pacients	Dades Eco-Adm	Assaigs en reclutament	pacients
Investigadors	Oncologia Mèdica		21	39		26	87
Coordinadors	Hematologia		7	24		10	18
Data Entry	Oncologia Radioteràpica		0	0		0	0
	Altres		0	0		1	3
Total			28	63		37	108

Core Facilities Activity (2018)


	# Services	# PI users	# New services offered	# Training/ divuligation activities
Flow Citometry	710	26	6	3
Electron microscopy unit	15	8	1	2
Genomics	1680 samples	7	2	7
Molecular Interactions	1591 hours	8	1	13
Molecular biology	141	3	1	2
Mouse Unit	95	2	2	1
Clinical Proteomics	1404	24	6	4
Advanced cell & tissue models	4	3	3	1
Histology	146	37	7	5

Core Facilities Activity (2019)

Biobank



Bioinformatics



Agenda

1. Research & Innovation activity summary
2. Research Support
- 3. Research Organization and changes**
4. IDIBELL external evaluations
5. Scientific Advisory Board Meeting – May 2019
6. Follow-up Strategic Plan
7. IRISCAT
8. IDIBELL institutional actions


3


Research organization and changes

- 2019 research organization
- Research PROGRAMS: Calls for program coordinators & ONCOBELL and NEUROBELL main achievements
- Research GROUPS: Changes in group leaders & group evaluation
- Tenure Tracks
- CMRB merging
- PEBC leaving to IJC

RESEARCH ORGANIZATION

2019
-
2022





RAMON SALAZAR

(1) Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell)




ISABEL FABREGAT



ESTEVE FERNANDEZ

(2) Epidemiology, Public Health, Cancer Prevention and Palliative Care




ANGEL RAYA

(4) Regenerative Medicine



FRANCISCO CIRUELA

(3) Neuroscience



ÀNGEL CEQUIER

(7) Cardiovascular, Respiratory and Systemic Diseases and cellular aging




VIRGINIA NUNES

(6) Genes, Disease and Therapy



EDUARD MONTANYA
(5) Diabetes and Metabolism Program



JOSEP M. LLOP

(8) Digestive system, diagnostics, pharmacogenetics, care support and clinical prevention



JORDI CARRATALÁ

(9) Infectious disease and transplantation Program

Structural Budget - Programs

ÀREA	PROGRAMA	Personnel	Program Coordination	Total	%
Cancer	CANCER AREA	1.238.313 €	122.216 €	1.360.529 €	59%
	Molecular Mechanisms and Experimental Therapy in Oncology Program	1.169.389 €	72.216 €	1.241.605 €	54%
	Epidemiology, Public Health, Cancer Prevention and Palliative Care Program	68.924 €	50.000 €	118.924 €	5%
Neuroscience	NEUROSCIENCE AREA	387.724 €	50.000 €	437.724 €	19%
	Neuroscience Program	387.724 €	50.000 €	437.724 €	19%
Traslational Medicine	TRASLATIONAL AREA	505.823 €	0 €	505.823 €	22%
	Infectious	135.677 €	0 €	135.677 €	6%
	Diabetes and Metabolism Program	0 €	0 €	0 €	0%
	Cardiovascular, Respiratory and Systemic Diseases and cellular aging Program	45.521 €	0 €	45.521 €	2%
	Digestive system, diagnostics, pharmacogenetics, care support and clinical prevention Program	0 €	0 €	0 €	0%
	Genes, Disease and Therapy Program	324.625 €	0 €	324.625 €	14%
TOTAL	TOTAL	2.131.859 €	172.216 €	2.304.075 €	100%

Calls for Program Coordinators 19

ONCOBELL



ONCOBELL – Nomination of Salazar & Fabregat co-coordinators (clinic&basic team) – **72.216 € / year**

NEUROBELL



NEUROBELL – Nomination of Ciruela
– **50.000€ / year**

EPIDEMIOLOG.



EPIDEMIOLOGY, PUBLIC HEALTH, CANCER PREVENTION AND PALLIATIVE CARE – Nomination of E. Fernández –
50.000€ / year

ONCOBELL Program



MAIN OBJECTIVE


To increase the scientific impact and visibility of the program. To improve the “bench to bed” work.

STRATEGIC OBJECTIVES

1. Increase research funding and success in competitive and non-competitive calls (2M€)
2. Increase program visibility
3. Increase internal collaborations and training activities
4. Program evaluation & distribution of internal resources

Evolution ONCOBELL FUNDS

(COMP. VS NON-COMP. VS. TOTAL)



ONCOBELL Program



Internal Program Advisor's Commission to advise the components of our program when preparing proposals:

- **Plan Estatal (BME, BIO):** Isabel Fabregat, Joan Gil
- **FIS/CIBER/ISCIII:** Francesc Viñals, Xavier Matias Guiu, Conxi Lázaro, Mariona Graupera, Ramon Salazar
- **Marató TV3, AECC & Privates:** Gabi Capella, F Guedea, Victor Moreno, Ramon Salazar
- **ERC and other European Actions, WWCR:** Oriol Casanovas, Víctor Moreno
- **NIH and other US Programs:** George Thomas.

ONCOBELL Program



Increase internal collaborations and training activities

- Participation of groups in internal and external seminars (IDIBELL work in progress and PhD Day)
- Oncobell International Symposia.
- Scientific Retreat: all the basic groups collaborate with clinical researchers.

Budget Oncobell invested in supporting groups with contracts :

- end of thesis
- technical contracts to support the period waiting for the budget of a funded grant


Neuroscience Program




NEUROBELL



- PhD students (30.000 €)
- NeuroImpulse (10.000 €)
- Simposium (5.000 €)
- Formation (4.500 €)
- NeuroPrize (500 €)





RAMON SALAZAR

(1) Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell)




ISABEL FABREGAT



ESTEVE FERNANDEZ

(2) Epidemiology, Public Health, Cancer Prevention and Palliative Care




ANGEL RAYA

(4) Regenerative Medicine



FRANCISCO CIRUELA

(3) Neuroscience



VIRGINIA NUNES

(6) Genes, Disease and Therapy



ÀNGEL CEQUIER

(7) Cardiovascular, Respiratory and Systemic Diseases and cellular aging



JOSEP M. LLOP

(8) Digestive system, diagnostics, pharmacogenetics, care support and clinical prevention




JORDI CARRATALÁ

(9) Infectious disease and transplantation Program



EDUARD MONTANYA
(5) Diabetes and Metabolism Program



Changes in group leaders

Hereditary Cancer – Dr Conxi Lazaro
new co-group leader with Dr.
Capellá



**Cellular and Molecular
Neurobiology** - Dr Artur Llobet
(previous Dr. Solsona)



**Nephrology and renal
transplantation** – Dr JM Cruzado
(previous Dr. Grinyó)



Cardiovascular Diseases – Dr Josep
Comín (previous Dr. Cequier)



New IDIBELL Group

Vascular-related Disease

Dr. Mariona Graupera



Research group evaluation status

2017 – 2018

1 Research Program

- Oncobell Program (19 groups)

2018 – 2019

4 Research Programs (26 groups) – pending SAB report

- Genes, Disease and Therapy (4 groups)
- Neuroscience (9 groups)
- Epidemiology, Public Health, Cancer prevention and palliative care (4 groups)
- PEBC (9 groups)

2019 – 2020

4 Research Programs (21 groups) - ongoing

- Diabetes and metabolism (3 groups)
- Cardiovascular, Respiratory and Systemic Diseases and cellular aging (4 groups)
- Digestive system, diagnostics, pharmacogenetics, care support and clinical prevention (9 groups)
- Infectious disease and transplantation (5 groups)

Professional careers for researchers

42% of payroll PIs inside the professional career plan of IDIBELL

- R3A – 6 positions
- R3B – 1 position

1 Promotion R3B open

- R4 – 1 position

2 internal positions open

- R4-E Emeritus – 2 positions

IDIBELL seminars 2019

DISTRIBUTION OF SPEAKERS BY COUNTRY / REGION



8

AUSTRIA, DENMARK, GERMANY, GREECE,
SPAIN, THE NETHERLANDS, UK, USA

61.8%


NATIONAL

38.2%

INTERNATIONAL

SPEAKERS BY SEX

34
SPEAKERS *



SPEAKERS BY RESEARCH AREA

TRANSLATIONAL MEDICINE



NEUROSCIENCE



REGENERATIVE MEDICINE



CANCER



* OTHER (5)

IDIBELL Fellow's seminars 2019

13

EVENTS
JULY – DECEMBER 2019


ABOUT THE FELLOWS' SEMINARS

The **Fellows' seminar** series is open to all members of the IDIBELL community where PhD students and postdocs present their research in progress. The Fellows' seminars provide a forum for IDIBELL early-career researchers to discuss the results of their research with each other, as well as with more experienced researchers.


SPEAKERS BY SEX

26

SPEAKERS *



SPEAKERS BY RESEARCH AREA



Areté Program

IDIBELL Training and Career Development Program

63

HOURS OF TRAINING
SINCE OCTOBER 2019



A Knowledge & intellectual abilities



C Research governance & organization



B Personal effectiveness




D Engagement, influence & impact


PARTICIPANTS BY SEX

103

PARTICIPANTS *



PARTICIPANTS BY ROLE




* RESEARCH PROJECT MANAGER (4); OTHER (1)

Tenured researchers



CANCER

REGENERATIVE
MEDICINE



NEUROSCIENCE



TRASLATIONAL
MEDICINE

2015



SARA
LARRIBA



MARIONA
GRAUPERA



LAURA
VALLE



CRISTINA
MUÑOZ-
PINEDO



NÚRIA
LLOBERAS

2018



ÒSCAR
MTEZ-TIRADO



JULIÁN
CERÓN



ANA MARIA
SOLÁ

Under evaluation or tenured



CARLES
SORIANO



XAVIER
ALTAFAJ



STEPHANE
FOURCADE



ALESSANDRA
GIORGETTI




Current Tenure-track



CANCER



REGENERATIVE
MEDICINE



NEUROSCIENCE



TRASLATIONAL
MEDICINE



ESTELA
CÁMARA

To be in 2021



ÁLVARO
AYTÉS

To be in 2022



RAÚL
ZAMORA

To be in 2024



DAVID LLOBET



RUTH
RODRIGUEZ



MERITXELL
ROVIRA

To be in 2025



CAROLINA
FLORIAN



MIREIA PLAS

To be in 2026



JUAN JOSE
ROJAS

Gender issues at IDIBELL



Summit for
Women's
Advancement and
Leadership in
Health Research


22nd October 2019
Girona


- Equality Commission
- Review the Equality Plan (by 2020)

Women's advancement and leadership in the biomedical research centres of catalonia

'SHE FIGURES' FROM
THE 19 BIOMEDICAL
RESEARCH CENTRES

GENDER SCISSORS IN HOSPITAL-BASED BIOMEDICAL RESEARCH CENTRES,
2017 [2/6]





RAMON SALAZAR

(1) Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell)




ISABEL FABREGAT



ESTEVE FERNANDEZ

(2) Epidemiology, Public Health, Cancer Prevention and Palliative Care




ANGEL RAYA

(4) Regenerative Medicine



FRANCISCO CIRUELA

(3) Neuroscience



VIRGINIA NUNES

(6) Genes, Disease and Therapy




ÀNGEL CEQUIER

(7) Cardiovascular, Respiratory and Systemic Diseases and cellular aging



EDUARD MONTANYA
(5) Diabetes and Metabolism Program



JOSEP M. LLOP

(8) Digestive system, diagnostics, pharmacogenetics, care support and clinical prevention



JORDI CARRATALÁ

(9) Infectious disease and transplantation Program

REGENERATIVE MEDICINE AREA



**IDI
BELL**

Institut d'Investigació
Biomèdica de Bellvitge

CMR[B]^R

Centre de Medicina Regenerativa de Barcelona
Centro de Medicina Regenerativa de Barcelona
Center of Regenerative Medicine in Barcelona



Program for Regenerative Medicine –
ANGEL RAYA

1

RESEARCH
PROGRAMS

4

RESEARCH
GROUPS

162

TOTAL IMPACT
FACTOR

4,9

AVERAGE
IMPACT FACTOR

918 K€

FUNDS RAISED

CMRB's merging within IDIBELL

MAIN OBJECTIVES OF THE MERGING:

- To guarantee the **viability** of the CMR[B]
- To accomplish with the **original CMR[B]'s Mission**
- To **catalyze the clinical translation** of Regenerative Medicine strategies based on iPSC

SCIENTIFIC & ORGANIZATIONAL aspects for the merging process:

- Revision of IDIBELL bylaws
- Revision of **IDIBELL Boards & SAB**
- **New Scientific Area**
 - 2 New internal groups
 - Open call for collaborative consortia
- Program Director (A. Raya – 5y)
- Agreement on **success indicators**
- **Economical support to the program**

CMRB's merging within IDIBELL

Big figures: IDIBELL vs CMRB

	IDIBELL	CMR[B]
Personnel (labour contract)	487 (1357)	34
Income	28.922.044,28 €	3.943.574,88 €
Transfer from Generalitat	4.200.000 €	1.700.000 €
Assets/Liabilities	60.704.151,96 €	5.452.974,14 €
Owners Equity	-1.644.664,38 €	-258.888,11 €
Profit/Loss	-250.295,91 €	1.005.581,60 €

CMRB's merging within IDIBELL

- Official merging: **January 1st, 2020**
- **Subrogation of CMRB personnel** to IDIBELL (= conditions)
- @cmrb.eu will be re-directed to @idibell.cat
- **CMRB platforms** will be integrated within IDIBELL
- Review and build IDIBELL **internal communication strategy**
 - Current situation: Focus groups
 - Shared values
 - Welcome procedure (on-boarding)

PEBC researchers leaving to IJC – the process

- **Leaving personnel: Subrogation process** (duties in terms of confidentiality, IDIBELL affiliation and Intellectual Property rights)
- **Equipment transfer:** It belongs to the institution (agreement to transfer specific equipment under approval of both institutions)
- **Staff remaining:** Puri Muñoz, Ethel Queralt, Eva González-Suárez (Oncobell)
- **Biological samples and Data transfer:** MTA and DTA agreements are needed to comply with GDPR regulations

GDPR regulations

- ✓ New regulations of GDPR: **May 25th, 2018**
- ✓ **Diagnosis of the current situation** (External analysis – AT GROUP Consulting)
 - ✓ **Interviews with managers** and research support
 - ✓ **Interviews with selected IDIBELL researchers**
 - ✓ Definition of **Action Plan** for the adjustment to the new GDPR regulations
- ✓ **IDIBELL DPD = TIC Salut / IDIBELL DPD officer = Beatriz Pinilla**
- ✓ **Setting up of the IDIBELL Data Protection Commission** (specific training)
- ✓ **Incorporation of DP expert within the CEIm Bellvitge** (Laura Vilagrassa)

NEXT STEPS:

- **Information sessions (training) to IDIBELL researchers (PIs)**

PEBC researchers leaving to IJC – the process

- **Transfer of active competitive projects** : Only under approval of funding bodies
- **Transfer of active "innovation" projects**: Existing patents belongs to the institution; existing licenses can be transferred only under approval of the licensing company
- **Laboratory notebooks**: It belongs to the institution (copies can be transferred)

Laboratory notebooks policy


GOOD PRACTICE IN RESEARCH – CERCA CODE OF CONDUCT NOVEMBER 2018



The notebooks or documents are owned by the CERCA center where the work has been carried out.

IDIBELL LABORATORY NOTEBOOK



 Free to all IDIBELL affiliates
Will be available in Q1 2020

ACCURATE RECORD KEEPING



- Preliminary record used to establish ownership of an invention and dates of discovery



- Experiments can be repeated and the results replicated and confirmed



- Repository of all primary data and results

Agenda

1. Research & Innovation activity summary
2. Research Support
3. Research Organization and changes
- 4. IDIBELL external evaluations**
5. Scientific Advisory Board Meeting – May 2019
6. Follow-up Strategic Plan
7. IRISCAT
8. IDIBELL institutional actions

4

IDIBELL external Evaluations

- CERCA (Nov. 2018)
- ISCIII (April 2019)
- FCAECC (May 2019)

CERCA evaluation



RECOMMENDATIONS

- Strengthen our **internationalization** by encouraging scientists to apply international to **projects**, increasing our **international recruitments and leadership**
- Ensure **scientific replacement**
- Analyze the **evolution of clinical trials (focus on our niche of expertise)**
- Strengthen our **agreements and partnerships with companies**
- **Balance the financial situation** and develop **philanthropy strategy** by **organizing a committee of expert in business and industrial sector**
- **Optimal size** of the institute: To reach an appropriate critical mass in some groups and **focus in some specific areas**
- Need of an integrated strategy for **research data**

ISCIII re-certification

RECOMMENDATIONS

- Develop plans for the **integration and mentoring of groups**
- Improve **stabilization** by junior researchers training and remuneration
- Ensure recruitment of **clinical research staff**: generational replacement, intensification, etc.
- Improve **group assessment** and **synergies** among them
- Foster **exploitation of scientific platforms**
- Improve **quality indicators**: adaptation to the new GDPR requirements, inclusion of PE follow-up indicators, RRI actions and quality commission.

FCAECC certification

RECOMMENDATIONS

- Perform more **divulgence actions** to increase IDIBELL **external visibility**.
- Implementation of **RRI actions**
- Preparation and implementation of a **declaration of Conflict of Interest procedure**
- Revision of the **Good Practices Guide**

Agenda

1. Research & Innovation activity summary
2. Research Support
3. Research Organization and changes
4. IDIBELL external evaluations
- 5. Scientific Advisory Board Meeting – May 2019**
6. Follow-up Strategic Plan
7. IRISCAT
8. IDIBELL institutional actions

5

A close-up photograph of a person's hands holding a plant stem. The hands are positioned at the top and bottom of the frame, with the fingers gently gripping the stem. The plant stem is light-colored and has several small, dark, oval-shaped leaves or buds attached to it. The background is a soft, out-of-focus green, suggesting an outdoor setting with foliage.

Scientific Advisory Board meeting (May 2019)

SAB visit – May 2019 (preliminary)

RECCOMENDATIONS

- Better explain to the **new Coordinators** what **IDIBELL** is expecting from them
- **Increase the budget** to be assigned to **Program Coordinators** to reach program specific goals
- Pursue and strengthen **collaborations between basic and clinical researchers**
- **Generational renewal**, especially in the personnel linked to the *HUB*
- Increasing **transparency and communications** it would be easier to align (or re-align) groups to the IDIBELL strategy
- **Re-define priorities** to make the scientific **loss of PEBC** a **stimulating opportunity to re-design research strategies and goals** within the institute.

6

A close-up photograph of a person's hands holding a plant stem. The hands are positioned at the top and bottom of the frame, with the fingers gently gripping the stem. The plant has small, light-colored flowers and green leaves. The background is a soft, out-of-focus landscape with rolling hills and a clear sky.

Follow up of Strategic Plan 2018 - 2022

European reference in health sciences & Innovation



1 Encourage **internal synergies** and **external alliances**

2 New Research Area on **Regenerative Medicine** P-CMR[C]

3 Joint actions with hospitals to promote **clinical research**

4 **Personalized Medicine Strategy**

5 **Internationalization**

6 Foster **innovation** to improve our impact on citizens' health

Bellvitge Campus as a reality



8 Improve research **visibility**

9 Build the **IDIBELL community**

7 Deployment of a **Health Micro-Cluster**

10 **Responsible Research & Innovation Strategy**

Talent in health sciences



11 Comprehensive model for **IDIBELL people management**

12 Attract talented **junior researchers**

13 Attract and retain **senior researchers**

Sustainable growth




14 Ensure an **efficient & transparent** researcher-oriented organization

15 An **enabling environment** for research (support)

16 Increase **funding** sources

Quick wins

PE 18-19



Agenda

1. Research & Innovation activity summary
2. Research Support
3. Research Organization and changes
4. IDIBELL external evaluations
5. Scientific Advisory Board Meeting – May 2019
6. Follow-up Strategic Plan
7. **IRISCAT**
8. IDIBELL institutional actions

7

IRISCAT Alliance

Generalitat de Catalunya
Departament de Salut

Generalitat de Catalunya
Departament de la Presidència
Secretaria del Govern

Diligència per fer constar
que aquest Acord s'ha aprovat
en la sessió del Govern del dia

3 de desembre de 2019

El secretari del Govern

Acord del Govern pel qual es crea una Aliança estratègica entre els instituts de recerca i innovació en salut de l'Institut Català de la Salut (IRISCAT).

El Pla de Salut de Catalunya 2016-2020 del Departament de Salut és el marc de referència per a totes les actuacions públiques en matèria de salut que desenvolupa la Generalitat de Catalunya. Aquest Pla proposa, a l'eix sobre l'atenció a la qualitat, la incorporació d'una línia de recerca i innovació en salut (línia 7), l'objectiu fonamental de la qual és establir les estratègies en matèria de recerca i innovació en salut que fixa el Pla estratègic de recerca i innovació en salut 2016-2020.

Aliança IRISCAT


Aliança d'Instituts de Recerca i Innovació en Salut de Catalunya



Aliança IRISCAT

Acord de Govern (Consell executiu dia 3 de desembre de 2019) preveu la **creació d'un espai de treball cooperatiu entre els instituts de recerca i innovació** del sistema català de salut que **haurà de ser ratificat en els respectius òrgans de govern** de cada centre

L'objectiu de l'Aliança IRISCAT és desenvolupar **una estratègia coordinada per aprofitar millor els avantatges d'actuar de forma col·laborativa**, així com l'alt nivell d'estàndards de l'organització assistencial i de recerca per millorar la recerca translacional i clínica del sistema català de la salut i, en conseqüència, la salut de la població del país



Aliança IRISCAT: Pla Estratègic

--2 La durada de l'Aliança s'estableix inicialment en tres anys a comptar des de la seva aprovació. No obstant, aquest termini se subordina a allò que resulti del punt cinquè del present Acord.

--3 En el termini de 3 mesos des de l'aprovació d'aquest Acord, les Institucions i instituts de recerca inclosos en aquesta iniciativa han de confeccionar un Pla estratègic per al seu desenvolupament que contempli les necessitats i implicacions necessàries per a la seva implementació i l'assoliment de l'objectiu d'aprofitament i integració d'economies d'escala en els diferents àmbits d'actuació.

El "Pla estratègic IRISCAT" ha d'incorporar de manera transversal els principis de recerca i innovació responsable (RRI) i ha de vetllar perquè el Pla estratègic reculli les necessitats específiques de RRHH en l'àmbit de la recerca en salut.


Aliança IRISCAT: Conveni d'Adhesió

--4 Els set instituts de recerca i innovació en salut vinculats a l'Institut Català de la Salut han de subscriure un conveni específic, que ha de detallar els aspectes claus relatius a l'estructuració i la governança de la iniciativa que formarà part de Pla estratègic, en el qual s'establiran els recursos personals i econòmics que cada centre ha de dedicar a la posada en marxa i el desenvolupament de l'Aliança estratègica.

--5 En el termini màxim d'un any s'ha de proposar al Departament de Salut, per a la seva elevació al Govern, i d'entre les diverses alternatives que ofereix l'ordenament legal, la figura jurídica definitiva a través de la qual s'ha de desenvolupar l'Aliança estratègica que ara es configura. Aquesta proposta ha de contemplar la forma en la qual els instituts de recerca i innovació en salut que en formen part s'hi vincularan amb caràcter definitiu, així com els mecanismes d'incorporació futura d'altres instituts de recerca i innovació en salut que inicialment no formen part del projecte.

Agenda

1. Research & Innovation activity summary
2. Research Support
3. Research Organization and changes
4. IDIBELL external evaluations
5. Scientific Advisory Board Meeting – May 2019
6. IRISCAT
7. Follow-up Strategic Plan
8. **IDIBELL institutional actions**



8

IDIBELL Institutional actions

- IDIBELL 15th anniversary
- Obrim les portes: SINERGIA
- Salvem Vides

#IDIBELLturns15

Acte central de celebració del 15è aniversari Paranimf de la Universitat de Barcelona May 8th 2019



IDIBELL 15th anniversary

Welcome
Dr Domènec Escriu, Research Vicerector, University of Barcelona.

Opening lecture
Dr Gabriel Capellà, IDIBELL Director.

15th anniversary video
produced by IDIBELL's Communications & Scientific Culture unit.

A brighter future? How biomedicine is changing our lives
Dr Salvador Maqol, Professor of the University of Leicester and writer.

Eureka! (premiere on the occasion of IDIBELL's 15th anniversary)
Piano piece courtesy of composer **Xavier Pagès-Corella**,
Performed by **David Casanova**, musician.

Official speeches
Dr Ana Clapés, Deputy Director-General of the Catalan Institute of Oncology.
Dr Montserrat Figuerola, Manager of the Southern Metropolitan Area of the Catalan Institute of Health.
Dr Albert Barberà, General Director of Research and Innovation in Health, Health Department, Catalonia's Government.

Closing remarks
Dr Domènec Escriu, Research Vicerector, University of Barcelona.

Birthday cake and anniversary toast
University of Barcelona, Garden of the historic building.

Event presented by Miguel Hernández, PhD student at IDIBELL.

www.idibell.cat



Vídeo de l'acte central del 15è aniversari



Acte de celebració del 15è aniversari de l'IDI BELL al Paranimf...

#IDIBELLturns15

#IDIBELLstories: 15 vídeos basats en 15 casos d'èxit científic dels 15 anys d'història de l'IDIBELL



Cap a l'eliminació del càncer de c...
Dr Xavier Bosch (Infeccions i càncer) #IDIBELLstories...



There is strength in numbers: a j...
Dr Mariona Graupera (Tumour angiogenesis) and Dr Antoni Riera...



Designing a cancer-fighting virus
Dr Ramon Alemany (cancer virotherapy and immunotherapy)...



La informació és poder: models ...
Dr Víctor Moreno (Càncer Colorectal) #IDIBELLstories...



"All-in" per a la recerca en addicció...
Dr Fernando Fernández-Aranda (Psiquiatria i Salut Mental)



Family matters: new approaches ...
Dr Laura Valle (Hereditary cancer) #IDIBELLstories #IDIBELLturns15



Personalized medicine: a new ap...
Dr Oriol Bestard (Nephrology and renal transplantation)...



The end of AIDS? HIV infection a...
Dr Daniel Podzamczar (Infections of the respiratory tract and in...



The early bird gets the worm: fro...
Dr Marta Barrachina (Neuropathology) #IDIBELLstories...



Persevere to succeed: overcomin...
Dr Oriol Casanovas (Tumour angiogenesis) Dr Alberto Villanuev...



New uses for old drugs: advance...
Dr Eva González-Suárez (Transformation and Metastasis)...



Del laboratori al pacient: el viatge...
Dr Isabel Fabregat (TGF-beta i càncer)



Trencant l'escut: una aproximaci...
Dr Rafael Mániz (Immunitat innata i patologia del malalt crític)...



The future is smoke-free
Dr Esteve Fernández (Cancer control and prevention) #IDIBELLstories...



A breath of fresh air: new strateg...
Dr Josep Maria Aran (Immune-inflammatory Processes and Gene...



#IDIBELLturns15 - IDIBELL 15th a...
Reflecting and building upon its fifteen years of existence, this...

Vídeo especial 15è aniversari

#IDIBELLturns15

#IDIBELLSINERGIA: Jornada de Portes Obertes a L'IDIBELL



Sinergia LA FESTA

de la RECERCA i la
INNOVACIÓ en SALUT
de L'HOSPITALET

Hospital Duran i Reynals

Dissabte, 16 de novembre de 2019

De 10 a 14 h

inh Industry
Innovation
Health
in Hospital

<https://sinergia.idibell.cat>

OFF-Sinergia
14 Novembre



ID!escape

Escape room als
laboratoris



**Tapes
d'Innovació**




VISITA la
farmàcia robotitzada
de l'ICO



Gastronomia
i futur



VISITA el
nou bloc quirúrgic
del HUB



OBRA DE CAJAL
Lectura
dramatitzada
a la UB

Quinaciencia!



Monòlegs, música i esport!



**Fira
sal' Hut**

Les entitats
de recerca i innovació
en salut de L'H



Experimenta


Espai infantil i
familiar



#IDIBELLturns15

Acte clausura – Nadal a l'IDIBELL

Friday 20 at 10 am (Antic Hall Duran i Reynals)



XOCOLATADA / HOT COCOA PARTY

FRIDAY 20.12 | 10.00 | Antic Hall Duran i Reynals Hospital

IDI-TIONS, Xocolata i regals per a tothom!
IDI-XMAS Log, chocolate and presents for everybody!



TEATRE JOVENTUT –

Divendres 20 de Desembre a les 20.30h

CONCERT SOLIDARI:

La recaptació d'aquest concert es donarà a l'Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), i es destinarà a tasques de recerca.

“We save lives”

- First **global fundraising campaign** at IDIBELL
- Strategic objectives:




VISIBILITY
IDIBELL brand
Research programs



FUNDRAISING
Crowdfunding
Sponsors & philanthropy



AWARENESS
Research support
Sense of belonging



2019: Oncobell program

→ cancer research

- Personalized medicine
- Immunotherapy
- Support to young talented researchers



2020: Neurobell program

→ Neuroscience research

- Cognitive impairment
- Neurodegenerative diseases

SAVE THE DATE: APRIL 2ND (GALA DINNER)



Thank you!



 Director@idibell.cat



Idibell.cat